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Abstract
Introduction: Various agents used in breast cancer chemotherapy provoke DNA double-strand breaks (DSBs). DSB
repair competence determines the sensitivity of cells to these agents whereby aberrations in the repair machinery
leads to apoptosis. Proteins required for this pathway can be detected as nuclear foci at sites of DNA damage
when the pathway is intact. Here we investigate whether focus formation of repair proteins can predict
chemosensitivity of breast cancer.
Methods: Core needle biopsy specimens were obtained from sixty cases of primary breast cancer before and
18-24 hours after the first cycle of neoadjuvant epirubicin plus cyclophosphamide (EC) treatment. Nuclear focus
formation of DNA damage repair proteins was immunohistochemically analyzed and compared with tumor
response to chemotherapy.
Results: EC treatment induced nuclear foci of gH2AX, conjugated ubiquitin, and Rad51 in a substantial amount of
cases. In contrast, BRCA1 foci were observed before treatment in the majority of the cases and only decreased
after EC in thirteen cases. The presence of BRCA1-, gH2AX-, or Rad51-foci before treatment or the presence of
Rad51-foci after treatment was inversely correlated with tumor response to chemotherapy. DNA damage response
(DDR) competence was further evaluated by considering all four repair indicators together. A high DDR score
significantly correlated with low tumor response to EC and EC + docetaxel whereas other clinicopathological
factors analyzed did not.
Conclusions: High performing DDR focus formation resulted in tumor resistance to DNA damage-inducing
chemotherapy. Our results suggested an importance of evaluation of DDR competence to predict breast cancer
chemosensitivity, and merits further studying into its usefulness in exclusion of non-responder patients.
Introduction
Recent advances in chemotherapy have significantly
improved the prognosis of breast cancer patients. How-
ever, prediction of tumor sensitivity to chemotherapy
has not reached a high level of confidence, whereas
determining sensitivity to hormone therapy or trastuzu-
mab is relatively more established. Estrogen receptor
(ER), progesterone receptor (PR) and human epidermal
growth factor receptor (HER)2/ErbB2 are practical
benchmarks to exclude non-responding patients, and
tailoring treatment based on gene status significantly
optimizes the response rate of hormone therapy and
trastuzumab, respectively. Prediction of chemosensitivity
with equivalent accuracy is currently anticipated to
further improve breast cancer prognosis.
Anthracycline-based regimens, such as epirubicin plus
cyclophosphamide (EC), and taxanes represent the
major chemotherapeutic agents used in the breast can-
cer field [1,2]. Of these, anthracycline-based chemother-
apy induces DNA double-strand breaks (DSBs) [3,4],
the most cytotoxic DNA lesion, that leads cells into
apoptosis especially when relevant repair pathways
(represented by homologous recombination (HR) repair)
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damage repair competence varies among individual
breast tumors and closely correlates with chemosensitiv-
ity. For example, secondary mutations of BRCA1 or
BRCA2 (essential factors in the HR pathway) caused by
chemotherapy using cisplatin or poly(ADP-ribose) poly-
merase inhibitor in BRCA1/2-mutated cancers restore
the wild-type reading frame and, therefore, the tumor
acquires resistance to these drugs [6-8]. These facts
indicate that chemosensitivity of BRCA-associated can-
cers could be strongly affected by DNA damage repair
capability. Based on this evidence it has been suggested
that HR competence could be a potential biomarker for
chemosensitivity [9]. Rad51, a protein that plays a direct
role in HR, especially reflects the HR competence of
cells. Therefore, knowing its status is likely to be valu-
able when assessing HR competence in tumor cells in
order to instruct therapeutic decisions [9].
The HR pathway for DSB repair is executed by
sequential recruitment of repair proteins to chromatin
around DNA lesions. Accumulation of the proteins is
regulated by complex mechanisms that utilize phosphor-
ylation and ubiquitination modifications mediated by
kinases including ataxia telangiectasia mutated (ATM),
and at least four ubiquitin E3 ligases, RNF8, RNF168,
Rad18, and BRCA1 [10-17]. The Mre11-Rad50-Nbs1
complex first recognizes DSBs and recruits ATM. ATM
then phosphorylates the histone variant H2AX (gH2AX)
[18,19] that triggers accumulation of the downstream E3
ligases RNF8 [11-13,20] and RNF168 [14,15]. Lysine 63-
linked polyubiquitin chains built at the sites of DNA
damage by these E3 ligases next recruits the BRCA1-
Abraxas-RAP80 complex through the RAP80 compo-
nent, a protein that contains ubiquitin interacting motif
domains [21-23]. BRCA1 is then essential in order to
recruit repair effector proteins, including Rad51, that
perform HR through sister chromatid exchange [24,25].
D e p l e t i o no fa n yo n eo ft h e s ep r o t e i n sr e s u l t si nH R
deficiency accompanied by loss of Rad51 focus forma-
tion, causing cells to become hypersensitive to DSB-
inducing agents.
In this study we attempt to clarify the value of HR
competence for the prediction of breast cancer chemo-
sensitivity. One contention is that nuclear focus forma-
tion of repair proteins in baseline breast cancer tissues
is a response to spontaneous DNA damage during cell
p r o l i f e r a t i o na n d ,i nt u r n ,m a yr e p r e s e n tam a r k e ro f
HR competence of cells to exogenous DNA damage.
Therefore, it may predict tumor response to DNA
damage-inducing chemotherapy such as with EC. Also,
the focus formation after chemotherapy could provide
us with additional information regarding the DNA
damage-response capacity. To verify in vivo whether
focus formation of repair proteins actually occurs in
response to DNA damage-inducing chemotherapy and
whether it correlates with tumor fates after chemo-
therapy, we analyzed foci in core needle biopsy speci-
mens from breast cancer before and after neoadjuvant
EC treatment.
Materials and methods
Patients and tumors
Sixty patients with primary breast cancer (2 cm or lar-
ger) who consecutively underwent neoadjuvant che-
motherapy with EC followed by treatment with
docetaxel (DOC) at the Division of Breast and Endo-
crine Surgery, St. Marianna University School of Medi-
cine, Japan, were enrolled in the present study from
August 2005 to July 2007. Tumor specimens were
obtained by core needle biopsy prior to starting therapy
and 18 to 24 hours after the first cycle of EC treatment.
Informed consent for the additional core needle biopsy
and experimental use of tumor samples was obtained
for all patients in accordance with an approved Institu-
tional Review Board application (registration number
946).
The chemotherapy regimen consisted of four 21-day
cycles of EC (E: 80 mg/m
2 o nd a y1 ,C :6 0 0m g / m
2 on
day 1) followed by four 21-day cycles of DOC (75 mg/
m
2 on day 1). 75 mg/m
2 DOC was administrated four
times as total (only on day 1). There was no increase or
decrease of the dose. Tumor size was evaluated by
three-dimensional images obtained by helical computed
tomography CT scan with a teleradiologic image work-
station (ZIOSTATION®, Ziosoft Inc., Tokyo, Japan) at
baseline, 14 to 21 days after the last cycle of EC, and 21
days after the last cycle of DOC treatment. The effect of
chemotherapy on the tumor was assessed as the three-
dimensional volume reduction rate or tumor response rate.
The tumor response was evaluated either by Response Eva-
luation Criteria in Solid Tumors (RECIST) [26] or by the
three-dimensional volume evaluation defined as: complete
response (CR; disappearance of the disease), partial
response (PR; reduction of tumor volume of ≥65%), stable
disease (SD; volume reduction <65% or enlargement
≤73%), or progressive disease (PD; volume enlargement
≥73%). These are equivalent to CR (disappearance), PR
(reduction of ≥30%), SD (reduction <30% or enlargement
≤20%), or PD (enlargement ≥20%) in unidimensional
RECIST criteria, respectively (reviewed in [27]). We also
analyzed responses with a 50% border between PR and SD
(instead of 65%) to evaluate more resistant cases.
Immunohistochemical analysis
Immunohistochemical analysis was performed by
the DAKO EnVision system (DAKO, Copenhagen,
Denmark) with modifications. Formalin-fixed, paraffin-
embedded specimens were cut and heated in a water
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(pH 9.0, Dako, Carpinteria, CA, USA) for detection of
BRCA-1 or in 10 mM sodium citrate buffer (pH 6.0)
for gH2AX and Rad51. No pre-treatment was neces-
sary to detect conjugated ubiquitin. After quenching of
endogenous peroxidase, the sections were incubated
overnight at 4°C with primary antibody at the appro-
priate dilution [Additional file 1], washed with PBS,
and incubated with horseradish peroxidase-labeled
polymer conjugated secondary antibody (EnVision+
System, Dako, Carpinteria, CA, USA) for 30 minutes at
room temperature. Color development was achieved by
3, 3’-diaminobenzidine tetrahydrochloride. Effective-
ness and specificity of each antibody for the detection
of DNA damage-induced nuclear foci were verified
with cultured cells treated with ionizing radiation (IR)
or epirubicin. The immunofluorescent study has been
previously described [28,29]. The nuclear foci were
further analyzed with the protocol used in the tissue
stain. The intrinsic subtype[30] was approximated by
receptor status determined by standard immunohisto-
chemical and fluorescence in situ hybridization (FISH)
analyses: luminal A: ER+ and/or PR+ and HER2-;
luminal B: ER+ and/or PR+ and HER2+; HER2: ER-
and PR- and HER2+; triple negative: ER- and PR- and
HER2-. Tumors that were immunochistochemically
scored as 3+, or 2+ with FISH-positive, were regarded
as positive for HER2 status. Cytokeratin (CK) 5/6
expression was also examined to evaluate the basal-like
character.
Immunohistochemical scoring
Taking into consideration that all immunohistochem-
ical markers used in the study localize to sites of DNA
damage in the normal HR pathway, we only counted
cells displaying nuclear focus formation and disre-
garded cytoplasmic or diffuse nuclear staining. We
scored the nuclear foci staining as follows: 0 = no posi-
tive cells, 1 = less than 10% positive cells, 2 = 10% or
greater, but less than 80% positive cells, 3 = 80% or
greater positive cells. Two observers (HA and HK)
were blinded to the clinical information to avoid
observer subjectivity when evaluating the immunohis-
tochemical staining. To correlate staining with tumor
response, we divided the cases into negative and posi-
tive samples to simplify the statistical analyses. The
positive cases are a total of the categories with a foci
score of 1, 2 and 3. To assess the capacity of the DNA
damage response (DDR) using a more comprehensive
approach, we configured the DDR score by counting
the total number of positive factors present in baseline
foci of BRCA1, gH2AX and Rad51, and EC-induced
foci of Rad51, per case.
Statistical analysis
The variables measured in the study were first investi-
gated for association by the chi-squared contingency
table analysis. For rank correlation, Spearman’s method
was performed to determine the correlation between the
foci score of two repair proteins and to determine the
correlation between tumor response rate and focus for-
mation of each repair protein or DDR score. For para-
metric analyses of tumor volume reduction, Student’s
unpaired t-test and the Tukey-Kramer method were
performed for two-factor comparisons and multiple
comparisons, respectively. For evaluation of significance
of DDR score and other clinicopathological factors in
correlation with mean tumor volume reduction or
tumor response rate, variant analysis (univariate) or
logistic regression analyses (univariate and multivaliate),
respectively, were performed. All analyses were carried
out using Statview 5 statistical software (SAS Institute
Inc, Cary, NC, USA). Statistical significance was
declared for P values less than 0.05.
Results
Clinical and pathologic features
Sixty patients with primary breast cancer were included
in the present series. All tumors were diagnosed as inva-
sive ductal carcinoma. Patient clinical characteristics are
given in Table 1. All triple-negative tumors were posi-
tive for CK5/6 (therefore described as basal-like in
Table 1) whereas three cases of Luminal A, one case of
Luminal B and three cases of HER2 type were positive
for CK5/6. Three patients have one first-degree relative
with a history of breast cancer and two patients have
one second-degree relative with a history of breast or
ovarian cancer. All patients completed an EC plus DOC
Table 1 Patient characteristics
Characteristic
factor
Number of
patients
Characteristic
factor
Number of
patients
Age at treatment
start
Cancer stage
Median 50 I 0
Range 34-68 II 53
Lymph node metastasis III 5
Negative 36 IV 2
Positive 24 Intrinsic subtype*
Tumor stage Luminal A 37
T1 0 Luminal B 6
T2 54 HER2 11
T3 6 Basal-like 6
T4 0 Total 60
* intrinsic subtypes were approximated by immunohistochemical receptor
status. HER, human epidermal growth factor receptor.
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on tumor specimens before EC in two patients because
of insufficient tumor sample after reserving stocks for
clinical use. Tumor size evaluation by CT after treat-
ment with EC plus DOC was not performed for one
patient because of the patient’s condition. All but one
patient received breast surgery after EC and DOC.
Nuclear foci staining of DNA damage repair proteins
To assess the competence of the DSB repair pathway,
we immunohistochemically analyzed gH2AX, conjugated
ubiquitin, BRCA1, and Rad51 in nuclear foci based on
the idea that these candidates may represent a typical
course of the DSB repair cascade [31]. Of these, gH2AX
is the most upstream element, sequentially followed in
the cascade by conjugated ubiquitin, BRCA1, and
Rad51. Rad51 is the most downstream of these four pro-
teins and is directly involved in HR. However, it should
be mentioned that DNA repair failure due to genes at
the same level of or downstream of RAD51, such as
RAD51AP1 [32] or translesion DNA polymerases
[33,34], is an unlikely cause of loss of foci formation of
these proteins. In addition to untreated, baseline breast
cancer tissues, we analyzed the tissues 18 to 24 hours
after the first cycle of EC treatment to obtain further
information for the assessment of DNA repair capacity.
T h ea n t i b o d i e su s e di nt h i ss t u d ya r ec o m m o n l yu s e d
and well characterized in general. In addition we tested
background staining and confirmed the specific detec-
tion of nuclear foci at DSBs caused by IR or epirubucin
treatment (Figure 1).
The immunohistochemical analyzes revealed that in all
but two cases, the foci score of at least one of the repair
proteins was altered in response to EC treatment.
Representative data for immunohistochemical findings
of the nuclear focus formation of the repair proteins
before and after the first cycle of EC are shown in
Figure 2 with panels summarizing the foci scores of the
cases. Prior to EC treatment, samples were stained to
determine baseline staining of foci. The foci were posi-
tive for gH 2 A X( 2 0o f5 8c a s e s ) ,B R C A 1( 5 1o f6 0
cases), or Rad51 (11 of 58 cases) whereas no cases
exhibited foci staining for conjugated ubiquitin (0 of 60
cases). In response to EC treatment, the number of foci
staining positive for gH2AX (44 of 58 cases), conjugated
ubiquitin (26 of 60 cases), and Rad51 (31 of 58 cases)
increased, whereas foci staining for BRCA1 either
increased (9 of 60 cases), remained unchanged (38 of 60
cases) or decreased (13 of 60 cases). The reason why
BRCA1 foci staining decreased after treatment in some
cases is not clear at present but it could be implicated
in the presence of BRCA1 foci in normal S-phase that
colocalizes with proliferating cell nuclear antigen
(PCNA) at DNA replication fork [35]. The foci score of
BRCA1 after EC (EC-induced foci score) significantly
correlated with that of Rad51 (P = 0.0017; Table 2),
likely reflecting the requirement of BRCA1 for Rad51
recruitment at the site of DNA damage. However, no
other correlations between repair proteins were
observed, and no clear pattern combinations of repair
proteins emerged.
Association of focus formation of each repair protein with
tumor response to chemotherapy
To elucidate the possible association between DDR com-
petence and tumor response to chemotherapy, we corre-
lated the presence of individual repair proteins in foci
with tumor volume before and after chemotherapy.
Tumor volume was measured prior to chemotherapy to
establish the baseline volume. The mean volume reduc-
tion of tumors after EC and after EC and DOC was 59.7
± 25.8% and 76.0 ± 20.7% of baseline tumor volume,
respectively. We analyzed the presence of repair proteins
in foci before (baseline foci) and after EC treatment (EC-
induced foci), sorted them into positive and negative foci
groups for each individual repair protein, and then corre-
lated each group with tumor volume [Additional file 2].
There was a significant difference in tumor volume after
EC between BRCA1-positive and BRCA1-negative base-
line foci groups (82.1 ± 17.8% vs 55.7 ± 25.1%, P =
0.0039) [Additional file 2a]. We then performed the same
analysis after EC and DOC treatment. In addition to
BRCA1 (93.7 ± 6.6% vs 72.8 ± 20.7%, P = 0.0044), signifi-
cant differences in tumor volume were observed between
positive and negative gH2AX (78.4 ± 17.4% vs 65.6 ±
26.8%, P = 0.0429) and Rad51 baseline foci groups (78.1
± 18.9% vs 63.6 ± 24.4%, P = 0.0351) [Additional file 2b].
We next tested the correlation between scored foci
groups and the tumor response rate. The tumor
response rate was evaluated with RECIST or three-
dimensional volume reduction using either 65% or 50%
of the PR/SD border (as described in the Materials and
Methods). Tumor responses to EC and EC plus DOC
according to focus formation status are shown in Addi-
tional file 3. Contingency table analyses demonstrate sig-
nificant differences in the EC tumor response rate
between BRCA1-positive and BRCA1-negative baseline
foci groups and between Rad51-positive and Rad51-
negative EC-induced foci groups for all three criteria of
the response rate (ZIO 65%, ZIO 50%, RECIST). There
continued to be a significant difference in tumor
response rate after EC and DOC treatment between
Rad51-positive and Rad51-negative EC-induced foci
groups for all three criteria. In addition, when evaluated
with a three-dimensional volume reduction using 50% of
the PR/SD border, significant differences in the tumor
response rate to EC and DOC were observed between
Rad51-positive and Rad51-negative baseline foci groups.
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Page 4 of 11Figure 1 Immunohistochemistry controls and antibody specificity. (a) Immunohistochemical staining with control IgG for tumors after the
first cycle of epirubicin plus cyclophosphamide (EC) treatment (upper panel). Lower panel shows Rad51 staining for morphologically diagnosed
non-cancerous breast tissues (left upper part) and tumor (right lower part) after the first cycle of EC treatment. Although non-cancerous breast
cells also expressed nuclear foci formation the number and intensity was significantly lower than that in tumor cells. (b and c) DNA damage-
induced nuclear foci formations detected by antibodies used in the study. HeLa cells were either untreated (-), treated with 5 Gy ionizing
radiation (IR) or 0.2 μg/ml epirubicin (Epi), incubated for three hours and fixed. Cells were then subjected either to immunofluorescent analyses
with the indicated primary antibodies and (b) FITC- (green) or Rhodamine- (red) conjugated secondary antibodies, or (c) to the same protocol as
that used in the tissue stain. For immunofluorescent analyses the nucleus was counterstained with DAPI. Ub, conjugated ubiquitin.
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groups with tumor response rates, we further analyzed
t h ed a t aw i t hS p e a r m a n ’s rank correlation method.
When evaluated with three-dimensional volume reduc-
tion using 50% of the PR/SD border, Spearman’sa n a l y -
sis showed that the presence of BRCA1-positive baseline
foci associated with poor EC tumor response (P =
0.0067) [Additional file 3]. Spearman’sa n a l y s i sa l s o
demonstrated that the presence of Rad51-positive base-
line foci (P = 0.0078) or EC-induced foci (P = 0.0042)
[Additional file 3] associated with poor EC and DOC
tumor response.
Figure 2 Nuclear focus formation in response to chemotherapy. Tumor specimens were obtained by core needle biopsy before and 18 to
24 hours after the first cycle of epirubicin plus cyclophosphamide (EC) treatment. Immunohistochemical findings from representative cases for
gH2AX, conjugated ubiquitin (Ub), BRCA1, and Rad51 are shown. Graphs at right demonstrate changes in nuclear foci score after EC treatment in
all cases analyzed. The red, blue, and black lines indicate cases with increased, decreased, and unchanged scores, respectively. The thickness of
the lines proportionally reflects the number of cases. The thinnest line (gH2AX score 3 to 3) and the thickest line (Ub, score 0 to 0) represent 1
and 34 cases, respectively. n, number of cases analyzed.
Table 2 Correlation between EC-induced foci of Rad51
and BRCA1
BRCA1
0 1 2 3 Total
Rad51
0 7 10 2 0 19
1 3 24 9 2 38
20 0 2 0 2
Total 10 34 13 2 59
P = 0.0017
P value is from the Spearman’s rank correlation test. EC, epirubicin plus
cyclophosphamide.
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chemotherapy
The analysis correlating focus formation of BRCA1,
gH2AX, and Rad51 prior to treatment and of Rad51 foci
after EC treatment with the mean tumor volume reduc-
tion or tumor response rate [Additional files 2 and 3]
uncovers a significant inverse correlation with tumor
response for each of the four conditions. These data sup-
port the supposition that higher DDR competency pro-
duces tumors resistant to chemotherapy. To correlate
overall DDR competency with tumor reduction, we
devised a simple measurement to assess DDR competency.
Each patient case was analyzed for the presence of all four
of the above listed conditions and was assigned a DDR
score of 0 to 4 based on the number of conditions present.
This DDR score was then correlated with mean tumor
volume reductions. Number of cases in each DDR score is
shown in Table 3. As shown in Figure 3, both the mean
tumor volume reductions after EC (28.4 ± 28.1%) and
a f t e rE Ca n dD O C( 4 9 . 9±2 2 . 0 % )f o rD D Rs c o r e4( a l l
four conditions present) were the lowest among all the
scores. There were significant differences between score 4
and either score 0 or 2 for the mean tumor volume reduc-
tions after EC (Figure 3a) and between score 4 and either
score 0, 1 or 2 for the mean tumor volume reductions
after EC and DOC (Figure 3b), as judged by the Tukey-
Kramer multiple comparisons study setting P <0 . 0 5a sa
significance threshold. In addition, Spearman’sa n a l y s i s
showed that a high DDR score was associated with poor
tumor response rate after EC and DOC (P = 0.0031) when
evaluated with three-dimensional volume reduction using
50% of the PR/SD border (Table 3). A high DDR score
also tended to be associated with poor tumor response
rate after EC (P = 0.0639, Table 3).
The correlation between DDR score and the tumor
response prompted us to examine whether it has a sig-
nificant impact among other clinicopathological factors
including age, cancer stage, tumor size, nodal metastatic
status, and subtypes. None of these factors correlated
with DDR score (data not shown). The variant analysis
for mean tumor volume reduction after EC revealed
that only DDR score (P = 0.0069), but no other factors
correlated with the mean tumor volume reduction
(Table 4). The variant analysis for mean tumor volume
reduction after EC and DOC also demonstrated DDR
Table 3 Correlation between DDR score and tumor
response rate (ZIO 50%)
DDR score
0 1 2 3 4 Total
After EC
CR 1 0 1 0 0 2
PR 1 12 14 9 2 38
SD 0 3 8 3 4 18
Total 2 15 23 12 6 58
P = 0.0639
After EC + DOC
CR 1 1 3 1 0 6
PR 1 13 19 9 2 44
SD 0 0 1 2 4 7
Total 2 14 23 12 6 57
P = 0.0031
P values are from the Spearman’s rank correlation test. CR, complete response;
DDR, DNA damage response; EC, epirubicin plus cyclophosphamide; PR, partial
response; SD, stable disease.
Figure 3 Mean tumor volume reductions after (a) EC or (b) EC
and DOC according to DDR score. Error bars represent standard
deviation. Significance was analyzed by Tukey-Kramer test setting P
< 0.05 as significance threshold. DDR, DNA damage response; DOC,
docetaxel; EC, epirubicin plus cyclophosphamide.
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factor, followed by nodal status (P = 0.0201) and tumor
size (P = 0.0538, Table 4). In addition, univariate logistic
regression analysis showed that a high (3 and 4) DDR
score was most significantly associated with poor tumor
response after EC and DOC (P = 0.0095) when evalu-
ated with volume reductionu s i n g5 0 %o ft h eP R / S D
border, followed by tumor size (P = 0.0260), cancer
stage (P = 0.0465), and subtype (P = 0.0659, Table 5).
We then examined multivariate analysis with tumor
size, nodal status, subtype, and DDR score, the factors
that showed probable association with tumor response
rate in the univariate analysis. Cancer stage was omitted
because it was correlated with tumor size. Importantly
the result indicated that only the DDR score was signifi-
cantly associated with tumor response rate (P =0 . 0 4 0 2 )
independent of other factors analyzed (Table 6).
Discussion
In the present study using human tumor specimens we
show for the first time that DNA repair competence may
predict breast cancer sensitivity to DNA damage-inducing
chemotherapy. We selected gH2AX, conjugated ubiquitin,
BRCA1, and Rad51, proteins in the DSB repair cascade, to
assess DNA repair competence because accumulated evi-
dence demonstrates that inactivation of genes in the DSB
repair pathway results in cellular sensitivity to DNA
damage-inducing chemotherapy [16,29,31,36-38]. In our
study, these repair proteins dramatically responded to EC
treatment. The conjugated ubiquitin response was espe-
cially dramatic as approximately half of the cases analyzed
formed conjugated ubiquitin foci, compared with unde-
tectable foci formation prior to treatment. This suggests
that ubiquitination occurs in vivo during the DNA damage
response in an early stage after chemotherapy. However,
in spite of the dramatic response, we did not find any sig-
nificant correlation between conjugated ubiquitin foci for-
mation and tumor response. The reason is currently
unknown. One possibility is that this could be attributed
to the fact that ubiquitination is also involved in DNA
damage response pathways other than for DSBs.
We did not find certain trends of the combinations of
responding repair proteins. Several reasons could
account for this observation. First, the metabolism and
pharmacokinetics of the agents could vary per patient.
The ideal time to obtain the in vivo sample was, there-
fore, difficult to determine. The experimental design
employed in this study was not very robust in this way.
In cultured cells, gH2AX accumulates at sites of DNA
damage just minutes after the damage occurs, whereas
BRCA1 and Rad51 foci appear 30 minutes to several
hours afterwards [11,35,39,40]. In this study we har-
vested samples 18 to 24 hours after EC treatment
because the agents were still expected to be present in
patients and we also considered the patient’sc o n v e n i -
ence. However, the ideal timing remains to be deter-
mined if biopsy after chemotherapy is required.
The second reason for the diversity of the DDR
response could be attributed to the diversity of aberra-
tions of the genes responsible for DSB repair in each
breast cancer. Theoretically, defects in the recruitment
of upstream repair proteins could result in loss of down-
stream proteins at sites of DNA damage, and this has
been shown to be the case in many molecular biological
studies using cultured cells [10-15,21-23]. Furthermore,
it was also shown that Rad51 nuclear expression is
absent in tumors associated with BRCA2 mutation [41].
T h ep o s i t i v ec o r r e l a t i o nf o u n db e t w e e nE C - i n d u c e d
BRCA1 and Rad51 foci in this study (Table 2) may also
support this interpretation. In contrast, it was reported
that overexpression of Rad51 restored Rad51 focus for-
mation and rescued the sensitivity of BRCA1-deficient
cells to x-rays and cisplatin [42]. Importantly, up-regula-
tion of Rad51 was a common feature of BRCA1-defi-
cient breast tumors [42]. These data suggest that the
mechanism of DSB repair response in vivo is not simple
and that assessment of DSB repair aberrations in each
patient case is, therefore, unreasonable at present.
In an attempt to address this problem in our current
study, we assessed the comprehensive capacity of DSB
repair by incorporating multiple candidate factors into
one DDR score. We found that foci of BRCA1, gH2AX,
and Rad51 prior to treatment and EC-induced foci of
Rad51 correlated with tumor response when compared
either with the mean tumor volume reduction or the
tumor response rate. When incorporating these four fac-
tors into one DDR score a significant correlation was
observed with mean tumor volume reduction after EC,
whereas no other factors correlated with the mean
tumor volume reduction (Table 4 and Figure 3a).
Although it was not statistically significant, the similar
correlation was also observed between DDR score and
tumor response rate (Table 3). These correlations
became more significant after EC and DOC treatment
(Tables 3 to 5 and Figure 3b) and the DDR score was
an independent predictive factor of other factors includ-
ing tumor subtype when evaluated with volume reduc-
tion using 50% of the PR/SD border (Table 6). Recent
studies suggested that luminal tumors have low response
rate to neoadjuvant chemotherapy, whereas basal-like
and HER2+ tumors have higher response rates. For
example, it has been reported that clinical response rate
(CR and PR) to anthracyclin-based chemotherapy of
luminal A was 39%, whereas that of basal-like, which
has been implicated with BRCA1 dysfunction [43,44],
was 85% [45]. The response rates to EC treatment of
luminal A (15 of 37 cases, 40.5%) and basal-like (4 of 6
cases, 66.7%) subtypes in the current study were not
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could not find any correlation between subtype and
DDR score while DDR score independently predicted
the chemosensitivity. The result may reflect the fact that
luminal A tumors also include DNA damage-sensitive
tumors with defective HR pathways that can be counted
by the DDR score. Supporting this it has been shown
that tumors caused by BRCA2 deficiency mainly become
luminal A tumors [44,46,47].
The reason why the correlation between the DDR score
and tumor response after EC and DOC treatment became
more significant than that after EC is not clear at present.
As DOC does not induce DNA DSBs, the observed effect
is not likely to be due to the sensitivity to DNA damage in
those tumors. DOC might be more toxic for the cells with
gross genomic aberration caused by the pretreatment with
EC under the condition of being less HR competent.
Alternatively it is possible that time length after EC treat-
ment enhanced the difference of the outcome.
Table 4 Univariate analysis of variance for mean tumor
volume reduction
n Mean tumor volume
reduction (%) ± SD
P
After EC
Age (years)
-50 30 64.1 ± 25.9 0.1710
51- 29 54.9 ± 25.4
Cancer stage
II 53 61.5 ± 25.1 0.0962
III 5 55.7 ± 29.1
IV 2 21.9 ± 6.4
Tumor stage
T2 54 60.8 ± 25.3 0.3059
T3 6 21.9 ± 6.4
Nodal status
N- 24 62.7 ± 24.9 0.4557
N+ 36 57.6 ± 26.6
Subtype
Luminal A 37 58.8 ± 21.3 0.2923
Luminal B 6 72.9 ± 9.4
HER2 11 50.4 ± 36.4
Basal-like 6 69.4 ± 37.0
DDR score
0 2 94.6 ± 7.6 0.0069
1 15 57.3 ± 19.4
2 23 62.8 ± 22.9
3 12 61.1 ± 26.6
4 6 28.4 ± 28.1
After EC-DOC
Age
-50 30 80.6 ± 23.9 0.0804
51- 29 71.2 ± 15.7
Cancer stage
II 52 77.9 ± 19.8 0.1230
III 5 64.3 ± 25.7
IV 2 54.7 ± 17.6
Tumor stage
T2 53 77.7 ± 19.7 0.0538
T3 6 60.6 ± 24.7
Nodal status
N- 23 83.7 ± 14.3 0.0201
N+ 36 71.0 ± 22.7
Subtype
Luminal A 36 77.9 ± 16.1 0.0789
Luminal B 6 86.0 ± 9.5
HER2 11 62.4 ± 30.5
Basal-like 6 79.7 ± 24.8
DDR score
0 2 99.6 ± 0.6 0.0035
1 14 77.2 ± 13.2
2 23 81.0 ± 14.7
Table 4: Univariate analysis of variance for mean tumor
volume reduction (Continued)
3 12 70.7 ± 27.5
4 6 49.9 ± 22.0
DDR, DNA Damage Response; DOC, docetaxel; EC, epirubicin plus
cyclophosphamide; HER, human epidermal growth factor receptor; SD,
standard deviation.
Table 5 Univariate logistic regression analysis of factors
affecting tumor response rate (ZIO 50%)
Odds ratio (95% CI) P
After EC + DOC
Age (years)
<51 1.000
51≤ 0.800 (0.192-3.333) 0.7592
Cancer stage
II 1.000
III, IV 5.750 (1.028-32.174) 0.0465
Tumor stage
T2 1.000
T3 7.833 (1.279-47.964) 0.0260
Nodal status
N- 1.000
N+ 6.286 (0.730-54.110) 0.0942
Subtype
Luminal A, B 1.000
HER2, Basal-like 3.958 (0.913-17.154) 0.0659
DDR score
0, 1, 2 1.000
3, 4 9.423 (1.729-51.359) 0.0095
CI, confidence interval; DDR, DNA Damage Response; DOC, docetaxel; EC,
epirubicin plus cyclophosphamide; HER, human epidermal growth factor
receptor.
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Page 9 of 11Interestingly, DDR score group 4 consisted of cases
with poor tumor responses to chemotherapy when eval-
uated for both mean tumor volume reduction (Figure 3)
and tumor response rate (Table 3). This result may lead
to the possibility of using DDR status in the clinic to
predict and exclude non-responders to EC treatment. It
is noteworthy to point out that the HR repair cascade
for DSB contains many essential proteins other than
those tested in this study. By including select subsets of
proteins for analysis, it may be possible to identify non-
responders in order to avoid unnecessary chemotherapy.
Ideally in such cases, the levels of baseline foci present
prior to treatment would provide enough information to
determine appropriate treatment, preventing the need
for additional core needle biopsy after chemotherapy.
Conclusions
In conclusion, our results suggest the importance of
evaluating DDR competence to predict breast cancer
chemosensitivity and warrant further investigation into
i t se f f e c t i v e n e s sa saw a yt oe x c l u d en o n - r e s p o n d i n g
patients.
Additional file 1: Table S1. Antibodies used in the present
immunohistochemical study.
Additional file 2: Figure S1. Mean tumor volume reduction after EC (a)
or EC+DOC (b) according to the nuclear foci status for DNA repair
proteins.
Additional file 3: Table S2. Tumor response rate according to the
nuclear foci status for DNA repair proteins.
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